ESMO Voices from China | Professor Hongxia Wang: B7-H3-Targeted ADC SYS6043 Shows Encouraging Antitumor Activity and Manageable Safety in Advanced Breast Cancer
In recent years, antibody-drug conjugates (ADCs) have become a major force reshaping the treatment landscape of advanced breast cancer. However, significant challenges remain in the management of patients with resistance to multiple lines of therapy and those with difficult-to-treat disease, highlighting the urgent need for breakthroughs involving novel therapeutic targets. At the 2026 European Society for Medical Oncology (ESMO) Congress, Professor Hongxia Wang of Fudan University Shanghai Cancer Center presented safety and efficacy data for SYS6043, a B7-H3-targeted ADC, in patients with advanced breast cancer in a Rapid Oral presentation (Abstract No. 5RO). Following the presentation, Oncology Frontier interviewed Professor Hongxia Wang of Fudan University Shanghai Cancer Center at ESMO to discuss the rationale for selecting B7-H3 as a therapeutic target in advanced breast cancer, potential explanations for differences in efficacy across molecular subtypes, and the future positioning and development of B7-H3-targeted ADCs.









